Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Rhea-AI Summary

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered drug target discovery, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Investors can access the call via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through Compugen's website. A replay will be available on the website after the live event.

HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2025-results-on-wednesday-august-6-2025-302511823.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) release Q2 2025 earnings?

Compugen will release its Q2 2025 financial results on Wednesday, August 6, 2025, before U.S. markets open.

How can I access Compugen's Q2 2025 earnings call?

Investors can join the call at 8:30 AM ET by dialing 1-866-744-5399 (U.S.) or +972-3-918-0644 (International), or via webcast through Compugen's website.

Will there be a replay available of Compugen's Q2 2025 earnings call?

Yes, a replay of the earnings call will be available on Compugen's website following the live webcast.

What type of company is Compugen (CGEN)?

Compugen is a clinical-stage cancer immunotherapy company that pioneers predictive computational drug target discovery using AI/ML technology.